Total Payments
$1.7M
2024 Payments
$349,993
Companies
48
Transactions
2,580
Medicare Patients
28,909
Medicare Billing
$2.6M
Payment Breakdown by Category
Other$1.3M (77.8%)
Travel$166,817 (9.6%)
Consulting$106,553 (6.2%)
Research$66,100 (3.8%)
Food & Beverage$44,637 (2.6%)
Education$211.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 624 | 74.3% |
| Travel and Lodging | $166,817 | 447 | 9.6% |
| Consulting Fee | $106,553 | 36 | 6.2% |
| Unspecified | $66,100 | 4 | 3.8% |
| Honoraria | $50,900 | 14 | 2.9% |
| Food and Beverage | $44,637 | 1,442 | 2.6% |
| Acquisitions | $9,068 | 3 | 0.5% |
| Education | $211.66 | 10 | 0.0% |
Payments by Type
General
$1.7M
2,576 transactions
Research
$66,100
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $747,121 | 682 | $0 (2024) |
| United Therapeutics Corporation | $497,188 | 493 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $194,168 | 339 | $0 (2024) |
| Gilead Sciences, Inc. | $63,779 | 84 | $0 (2019) |
| Lexicon Pharmaceuticals, Inc. | $47,714 | 49 | $0 (2024) |
| SCPHARMACEUTICALS INC. | $44,292 | 18 | $0 (2024) |
| Merck Sharp & Dohme LLC | $33,843 | 47 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $32,870 | 101 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $23,162 | 248 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,738 | 64 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $349,993 | 302 | United Therapeutics Corporation ($121,897) |
| 2023 | $171,594 | 265 | Actelion Pharmaceuticals US, Inc. ($111,780) |
| 2022 | $228,427 | 333 | Actelion Pharmaceuticals US, Inc. ($105,417) |
| 2021 | $169,097 | 292 | Actelion Pharmaceuticals US, Inc. ($78,333) |
| 2020 | $119,764 | 216 | Actelion Pharmaceuticals US, Inc. ($50,841) |
| 2019 | $140,802 | 275 | Actelion Pharmaceuticals US, Inc. ($92,670) |
| 2018 | $255,561 | 444 | Actelion Pharmaceuticals US, Inc. ($103,171) |
| 2017 | $294,682 | 453 | Actelion Pharmaceuticals US, Inc. ($99,499) |
All Payment Transactions
2,580 individual payment records from CMS Open Payments — Page 1 of 104
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Asklepios Biopharmaceutical Inc. | — | Acquisitions | Cash or cash equivalent | $3,712.55 | General |
| 12/24/2024 | United Therapeutics Corporation | — | — | Cash or cash equivalent | $30,000.00 | Research |
| Study: PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.64 | General |
| Category: Cardiovascular | ||||||
| 12/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Honoraria | Cash or cash equivalent | $8,000.00 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Travel and Lodging | Cash or cash equivalent | $156.50 | General |
| Category: Cardiology | ||||||
| 12/06/2024 | United Therapeutics Corporation | REMODULIN (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $117.55 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $44.41 | General |
| 12/03/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $41.67 | General |
| Category: Heart Failure | ||||||
| 11/27/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $39.91 | General |
| Category: Heart Failure | ||||||
| 11/27/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Heart Failure | ||||||
| 11/26/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| 11/22/2024 | United Therapeutics Corporation | REMODULIN (Drug) | Travel and Lodging | In-kind items and services | $211.54 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.99 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.77 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $124.74 | General |
| 11/12/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $20.42 | General |
| 11/05/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/31/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $1,137.00 | General |
| Category: Cardio-pulmonary | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | United Therapeutics Corporation | $66,100 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 8,210 | 10,424 | $3.3M | $744,785 |
| 2022 | 24 | 7,671 | 9,897 | $3.2M | $707,803 |
| 2021 | 27 | 7,631 | 10,035 | $3.2M | $705,827 |
| 2020 | 21 | 5,397 | 7,031 | $1.7M | $425,146 |
Total Patients
28,909
Total Services
37,387
Medicare Billing
$2.6M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 2,198 | 2,272 | $1.7M | $318,065 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,033 | 1,447 | $535,390 | $131,711 | 24.6% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 133 | 139 | $121,594 | $83,453 | 68.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 971 | 979 | $239,855 | $59,281 | 24.7% |
| 94621 | Test for exercise-induced heart and lung stress | Office | 2023 | 283 | 303 | $133,320 | $31,750 | 23.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 202 | 202 | $97,162 | $21,662 | 22.3% |
| 93050 | Analysis of central arterial pressure with review by physician | Office | 2023 | 1,113 | 1,810 | $108,600 | $20,586 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 122 | 145 | $75,110 | $17,812 | 23.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,040 | 1,275 | $118,575 | $11,946 | 10.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $41,976 | $10,360 | 24.7% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 283 | 303 | $33,330 | $8,341 | 25.0% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 67 | 136 | $13,600 | $4,755 | 35.0% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 102 | 307 | $27,630 | $4,424 | 16.0% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 66 | 178 | $21,360 | $3,767 | 17.6% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 40 | 131 | $28,820 | $3,189 | 11.1% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 136 | 141 | $12,690 | $2,675 | 21.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 173 | 268 | $4,020 | $2,236 | 55.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 11 | 64 | $9,088 | $2,196 | 24.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 11 | 59 | $9,794 | $1,935 | 19.8% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 60 | 91 | $4,004 | $1,295 | 32.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 45 | 49 | $6,370 | $1,248 | 19.6% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 21 | 23 | $4,830 | $943.84 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 19 | $4,940 | $716.20 | 14.5% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 15 | 17 | $1,649 | $439.04 | 26.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 2,205 | 2,310 | $1.7M | $332,320 | 19.4% |
About Dr. Hunter Champion, M.D
Dr. Hunter Champion, M.D is a Cardiovascular Disease healthcare provider based in Columbus, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285683755.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hunter Champion, M.D has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $349,993 received in 2024. These payments were reported across 2,580 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Champion has provided services to 28,909 Medicare beneficiaries, totaling 37,387 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Columbus, GA
- Active Since 05/10/2006
- Last Updated 03/17/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1285683755
Products in Payments
- UPTRAVI (Drug) $559,351
- Adempas (Drug) $191,013
- ORENITRAM (Drug) $176,568
- TYVASO (Drug) $70,211
- OPSUMIT MACITENTAN (Drug) $52,219
- Inpefa (Drug) $47,671
- FUROSCIX (Drug) $44,292
- NONE (Drug) $40,652
- OPSUMIT (Drug) $32,810
- ENTRESTO (Drug) $32,646
- Letairis (Drug) $27,781
- XARELTO (Drug) $23,161
- WINREVAIR (Biological) $17,857
- REMODULIN (Drug) $15,071
- FARXIGA (Drug) $12,434
- VYNDAQEL (Drug) $10,071
- ONPATTRO (Drug) $5,033
- Kerendia (Drug) $1,556
- ELIQUIS (Drug) $1,047
- Repatha (Biological) $500.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Columbus
Gary Ansel, Md, MD
Cardiovascular Disease — Payments: $4.6M
Cardiovascular Disease $4.6M
Steven Yakubov, Md, MD
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Mitchell Silver, Do, DO
Cardiovascular Disease — Payments: $781,405
Cardiovascular Disease $781,405
Rami Kahwash, M.d, M.D
Cardiovascular Disease — Payments: $425,557
Cardiovascular Disease $425,557
John Phillips, M.d, M.D
Cardiovascular Disease — Payments: $395,324
Cardiovascular Disease $395,324
John Hummel, M.d, M.D
Cardiovascular Disease — Payments: $300,333
Cardiovascular Disease $300,333